DK3442547T3 - Lactobacillus reuteri MM4-1A til anvendelse i behandling eller forebyggelse af autismespektrumforstyrrelser - Google Patents

Lactobacillus reuteri MM4-1A til anvendelse i behandling eller forebyggelse af autismespektrumforstyrrelser Download PDF

Info

Publication number
DK3442547T3
DK3442547T3 DK17783343.1T DK17783343T DK3442547T3 DK 3442547 T3 DK3442547 T3 DK 3442547T3 DK 17783343 T DK17783343 T DK 17783343T DK 3442547 T3 DK3442547 T3 DK 3442547T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
lactobacillus reuteri
autism spectrum
spectrum disorders
Prior art date
Application number
DK17783343.1T
Other languages
English (en)
Inventor
Mauro Costa-Mattioli
Shelly Alexandra Buffington
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Application granted granted Critical
Publication of DK3442547T3 publication Critical patent/DK3442547T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK17783343.1T 2016-04-15 2017-04-15 Lactobacillus reuteri MM4-1A til anvendelse i behandling eller forebyggelse af autismespektrumforstyrrelser DK3442547T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662322946P 2016-04-15 2016-04-15
PCT/US2017/027827 WO2017181158A1 (en) 2016-04-15 2017-04-15 Probiotic therapies for developmental disorders and other neurological disorders

Publications (1)

Publication Number Publication Date
DK3442547T3 true DK3442547T3 (da) 2023-09-04

Family

ID=60042831

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17783343.1T DK3442547T3 (da) 2016-04-15 2017-04-15 Lactobacillus reuteri MM4-1A til anvendelse i behandling eller forebyggelse af autismespektrumforstyrrelser

Country Status (14)

Country Link
US (2) US11135252B2 (da)
EP (2) EP4238573A1 (da)
DK (1) DK3442547T3 (da)
ES (1) ES2954147T3 (da)
FI (1) FI3442547T3 (da)
HR (1) HRP20231030T1 (da)
HU (1) HUE062788T2 (da)
LT (1) LT3442547T (da)
PL (1) PL3442547T3 (da)
PT (1) PT3442547T (da)
RS (1) RS64503B1 (da)
SI (1) SI3442547T1 (da)
SM (1) SMT202300283T1 (da)
WO (1) WO2017181158A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231030T1 (hr) * 2016-04-15 2023-12-22 Baylor College Of Medicine Lactobacillus reuteri mm4-1a za upotrebu u liječenju ili prevenciji poremećaja autističnog spektra
KR102463809B1 (ko) * 2019-05-24 2022-11-04 한국식품연구원 클로스트리디오이데스 디피실레에 항균 활성을 갖는 락토바실러스 파라카세이 WiKim0110 균주 및 이를 포함하는 조성물
CN115279194A (zh) * 2020-01-13 2022-11-01 赛欧托生物科技股份有限公司 治疗或改善自闭症和相关病症的方法
CA3205469A1 (en) * 2020-12-18 2022-06-23 The General Hospital Corporation Probiotics compositions and method of using the same to enhance growth and social function in children
CN117320566A (zh) * 2020-12-30 2023-12-29 通用医疗公司 用于治疗自闭症谱系障碍的方法和组合物
CN113180109B (zh) * 2021-04-16 2022-02-18 段云峰 罗伊氏乳杆菌在制备预防或治疗发育障碍类疾病产品中的应用
CN113073066B (zh) 2021-04-16 2022-01-04 段云峰 罗伊氏乳杆菌及其应用、组合物、药物和食品
US12005044B1 (en) 2022-11-29 2024-06-11 Autism Therapeutics Inc. Treatment of autism spectrum disorders with ergothioneine, selenoneine, or combinations thereof
US20240252558A1 (en) * 2023-01-29 2024-08-01 The University Of Chicago Probiotics to rescue maternal immune activation-induced neurodevelopment deficits
JPWO2024242147A1 (da) * 2023-05-22 2024-11-28

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413960A (en) 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
ES2353690T3 (es) 2002-10-03 2011-03-04 Neuropharmacology Services, Llc Oxitocina para su uso en el tratamiento del autismo y del trastorno de asperger.
US7344867B2 (en) 2005-04-15 2008-03-18 Eamonn Connolly Selection and use of lactic acid bacteria for reducing inflammation in mammals
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
US20100063002A1 (en) 2007-03-13 2010-03-11 Bernd Stahl Method of improving skills with a composition comprising non-digestible saccharide
CN102202527B (zh) * 2008-11-03 2014-12-31 雀巢产品技术援助有限公司 包含益生菌并改善睡眠模式的营养组合物
JP2013507394A (ja) 2009-10-09 2013-03-04 プロセラ インコーポレイテッド 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法
MY191538A (en) * 2010-12-31 2022-06-30 Abbott Lab Human milk oligosaccharides to promote growth of beneficial bacteria
EP2609814A1 (en) 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of cognitive function
EP2609813A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
HRP20231030T1 (hr) * 2016-04-15 2023-12-22 Baylor College Of Medicine Lactobacillus reuteri mm4-1a za upotrebu u liječenju ili prevenciji poremećaja autističnog spektra

Also Published As

Publication number Publication date
SMT202300283T1 (it) 2023-11-13
EP3442547A4 (en) 2019-11-27
EP3442547A1 (en) 2019-02-20
FI3442547T3 (fi) 2023-09-05
EP3442547B1 (en) 2023-06-07
US20210379123A1 (en) 2021-12-09
SI3442547T1 (sl) 2023-11-30
HUE062788T2 (hu) 2023-12-28
LT3442547T (lt) 2023-09-25
ES2954147T3 (es) 2023-11-20
RS64503B1 (sr) 2023-09-29
HRP20231030T1 (hr) 2023-12-22
PT3442547T (pt) 2023-09-04
WO2017181158A1 (en) 2017-10-19
US11135252B2 (en) 2021-10-05
US20190070226A1 (en) 2019-03-07
EP4238573A1 (en) 2023-09-06
PL3442547T3 (pl) 2023-10-23

Similar Documents

Publication Publication Date Title
IL279752A (en) Polycyclic compounds and use thereof in the treatment of immune disorders
DK3442547T3 (da) Lactobacillus reuteri MM4-1A til anvendelse i behandling eller forebyggelse af autismespektrumforstyrrelser
DK3212208T3 (da) Anvendelse af l. reuteri til forebyggelse eller behandling af mikrobiotadysbiose tidligt i livet
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
DK3149019T3 (da) Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme
DK3490582T3 (da) Sammensætninger til anvendelse i behandling af myelofibrose
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
DK2981274T3 (da) Probiotiske stammer til anvendelse ved behandling eller forebyggelse af osteoporose
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3442513T3 (da) Anvendelse af cannabidiolsyre i behandling af autismespektrumforstyrrelse og forbundne forstyrrelser
SG10202013034QA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
GB2549278B (en) Use of cannabidivarin in the treatment of autism spectrum disorder
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3484585T3 (da) Anvendelse af probiotika ved behandling og/eller forebyggelse af atopisk dermatitis
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
IL251904A0 (en) Apilimod for use in the treatment of melanoma
DK3191103T3 (da) Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner
DK3153511T3 (da) 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme
IL247435A0 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
DK3122367T3 (da) Sammensætninger baseret på safran til forebyggelse og/eller behandling af degenerative øjenlidelser
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii